Post by Deleted on Mar 27, 2019 13:31:10 GMT
ROCKVILLE, M.D., March 27, 2019 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat, today announced that it will present four scientific posters at the 2019 American Association for Cancer Research (AACR) Annual Meeting, which will be held from March 29 – April 3, 2019 in Atlanta, Georgia.
Details of the poster presentations are as follows:
Title: Phenotyping pancreatic cancer CTCs as biomarkers for RX-3117 clinical trial
Session Date and Time: Sunday, March 31, 2019 1:00 PM - 5:00 PM
Session Title: Circulating and Cell-free Biomarkers for Diagnosis and Monitoring of Cancer 1
Location: Georgia World Conference Center, Exhibit Hall B, Poster Section 17
Abstract Number: 428
Abstract Link: www.abstractsonline.com/pp8/#!/6812/presentation/7993
Title: RX-5902 exhibits direct and immunomodulatory anti-tumor activities in melanoma PDX models
Session Date and Time: Tuesday, April 2, 2019 1:00 PM - 5:00 PM
Session Title: Novel Immunomodulatory Agents 2
Location: Georgia World Conference Center, Exhibit Hall B, Poster Section 25
Abstract Number: 4127
Abstract Link: www.abstractsonline.com/pp8/#!/6812/presentation/3309
Title: The anticancer effects of RX-5902 result from inhibition of phosphorylated p68-mediated β-catenin nuclear translocation
Session Date and Time: Monday, April 1, 2019 8:00 AM - 12:00 PM
Session Title: Novel Targets and Pathways
Location: Georgia World Conference Center, Exhibit Hall B, Poster Section 14
Abstract Number: 1298
Abstract Link: www.abstractsonline.com/pp8/#!/6812/presentation/5514
Title: Unusual mechanism of resistance to the novel cytidine analog fluorocyclopentenylcytosine (RX-3117)
Session Date and Time: Monday, April 1, 2019 8:00 AM - 12:00 PM
Session Title: Drug Resistance 2
Location: Georgia World Conference Center, Exhibit Hall B
Abstract Number: 1267
Abstract Link: www.abstractsonline.com/pp8/#!/6812/presentation/1631
Copies of the abstracts are available and can be viewed online through the AACR website at www.aacr.org. Once presented, copies of the posters will be available on the company’s website at rexahn.com/cms/media-center/publication/posters/.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals Inc. (NYSE American: RNN) is a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat. The Company’s mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn’s product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Preclinical studies show that several of Rexahn’s product candidates may be effective against multiple types of cancer, including drug resistant cancers, and difficult-to-treat cancers and others may augment the effectiveness of current FDA-approved cancer treatments. The Company has two oncology product candidates, RX-3117 and RX-5902, in Phase 2 clinical development and additional compounds in preclinical development, including RX-0301. For more information about the Company and its oncology programs, please visit www.rexahn.com.
=================================
C L
Details of the poster presentations are as follows:
Title: Phenotyping pancreatic cancer CTCs as biomarkers for RX-3117 clinical trial
Session Date and Time: Sunday, March 31, 2019 1:00 PM - 5:00 PM
Session Title: Circulating and Cell-free Biomarkers for Diagnosis and Monitoring of Cancer 1
Location: Georgia World Conference Center, Exhibit Hall B, Poster Section 17
Abstract Number: 428
Abstract Link: www.abstractsonline.com/pp8/#!/6812/presentation/7993
Title: RX-5902 exhibits direct and immunomodulatory anti-tumor activities in melanoma PDX models
Session Date and Time: Tuesday, April 2, 2019 1:00 PM - 5:00 PM
Session Title: Novel Immunomodulatory Agents 2
Location: Georgia World Conference Center, Exhibit Hall B, Poster Section 25
Abstract Number: 4127
Abstract Link: www.abstractsonline.com/pp8/#!/6812/presentation/3309
Title: The anticancer effects of RX-5902 result from inhibition of phosphorylated p68-mediated β-catenin nuclear translocation
Session Date and Time: Monday, April 1, 2019 8:00 AM - 12:00 PM
Session Title: Novel Targets and Pathways
Location: Georgia World Conference Center, Exhibit Hall B, Poster Section 14
Abstract Number: 1298
Abstract Link: www.abstractsonline.com/pp8/#!/6812/presentation/5514
Title: Unusual mechanism of resistance to the novel cytidine analog fluorocyclopentenylcytosine (RX-3117)
Session Date and Time: Monday, April 1, 2019 8:00 AM - 12:00 PM
Session Title: Drug Resistance 2
Location: Georgia World Conference Center, Exhibit Hall B
Abstract Number: 1267
Abstract Link: www.abstractsonline.com/pp8/#!/6812/presentation/1631
Copies of the abstracts are available and can be viewed online through the AACR website at www.aacr.org. Once presented, copies of the posters will be available on the company’s website at rexahn.com/cms/media-center/publication/posters/.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals Inc. (NYSE American: RNN) is a clinical stage biopharmaceutical company developing innovative therapies to improve patient outcomes in cancers that are difficult to treat. The Company’s mission is to improve the lives of cancer patients by developing next-generation cancer therapies that are designed to maximize efficacy while minimizing the toxicity and side effects traditionally associated with cancer treatment. Rexahn’s product candidates work by targeting and neutralizing specific proteins believed to be involved in the complex biological cascade that leads to cancer cell growth. Preclinical studies show that several of Rexahn’s product candidates may be effective against multiple types of cancer, including drug resistant cancers, and difficult-to-treat cancers and others may augment the effectiveness of current FDA-approved cancer treatments. The Company has two oncology product candidates, RX-3117 and RX-5902, in Phase 2 clinical development and additional compounds in preclinical development, including RX-0301. For more information about the Company and its oncology programs, please visit www.rexahn.com.
=================================
C L